CLAIMS

1. A lyophilate comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate and a stabilizing agent.

2. The lyophilate of claim 1, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/stabilizing agent weight ratio is about 0.67.

3. The lyophilate of claim 1, wherein the stabilizing agent is polyvinylpyrrolidone.

4. The lyophilate of claim 1 further comprising a buffering agent.

5. The lyophilate of claim 4, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate/buffering agent weight ratio is about 6.5.

6. The lyophilate of claim 4, wherein buffering agent is L-histidine.

7. The lyophilate of claim 1 comprising about 42 mg of (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate.

8. The lyophilate of claim 1 further comprising about 63 mg of polyvinylpyrrolidone.

9. A pharmaceutical composition comprising the lyophilate of any one of claims 1-8, wherein the lyophilate is reconstituted in a solvent, wherein the solvent comprises ethanol and water.

10. The pharmaceutical composition of claim 9, wherein the solvent comprises about 45% to about 55% ethanol and about 55% to about 45% water.

11. The pharmaceutical composition any one of claims 9 or 10, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate concentration is about 10 mg/mL.

12. A pharmaceutical formulation comprising the pharmaceutical composition of any one of claims 9-11 and a diluent.

13. The pharmaceutical formulation of claim 12, wherein the (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate concentration is about 0.012 to about 0.24 mg/mL.

14. Use of the pharmaceutical formulation of claims 12 or 13 in the manufacture of a medicament for the treatment of cancer.

15. The use of claim 14, wherein the pharmaceutical formulation is to be administered intravenously to the subject.

16. A method of making the lyophilate of any one of claims 1-8, the method comprising:

(i) dissolving (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate in a mixture of t-butanol, ethanol, and water at a temperature of about 25 ºC to about 35 ºC to give a pre-lyophilization solution;

(ii) cooling the pre-lyophilization solution until it is frozen or partially frozen; and

(iii) applying a vacuum to the frozen or partially frozen pre-lyophilization solution to give the lyophilate.

17. The method of claim 16, wherein the pre-lyophilization solution further comprises polyvinylpyrrolidone and L-histidine.

18. The method of claim 16, wherein the concentration of (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate in the pre-lyophilization solution is about 10 mg/mL.

19. A kit comprising the lyophilate of claim 1 packaged as single unit dose in a vial.

20. The use of claim 14, wherein the cancer is hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, or colorectal cancer.